ProfileGDS4814 / ILMN_1658425
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 90% 88% 88% 91% 88% 88% 86% 90% 90% 86% 90% 89% 90% 88% 90% 90% 88% 90% 91% 90% 89% 91% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)398.46890
GSM780708Untreated after 4 days (C2_1)314.70988
GSM780709Untreated after 4 days (C3_1)311.11988
GSM780719Untreated after 4 days (C1_2)458.7491
GSM780720Untreated after 4 days (C2_2)329.89388
GSM780721Untreated after 4 days (C3_2)313.1388
GSM780710Trastuzumab treated after 4 days (T1_1)255.03886
GSM780711Trastuzumab treated after 4 days (T2_1)397.3990
GSM780712Trastuzumab treated after 4 days (T3_1)407.24990
GSM780722Trastuzumab treated after 4 days (T1_2)264.67286
GSM780723Trastuzumab treated after 4 days (T2_2)391.65790
GSM780724Trastuzumab treated after 4 days (T3_2)357.30389
GSM780713Pertuzumab treated after 4 days (P1_1)396.75590
GSM780714Pertuzumab treated after 4 days (P2_1)313.81388
GSM780715Pertuzumab treated after 4 days (P3_1)418.41190
GSM780725Pertuzumab treated after 4 days (P1_2)406.36390
GSM780726Pertuzumab treated after 4 days (P2_2)312.39388
GSM780727Pertuzumab treated after 4 days (P3_2)397.3990
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)470.97391
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)422.63390
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)344.88189
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)452.11591
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)402.01690